Astrana Health, Inc. Q1 FY2026 earnings call

Emphasize the advantages of the Astrana platform in healthcare ecosystem integration, AI embedding across workflows. Prospect integration progress, including financial standardization and clinical workflow alignment. Execution across strategic pillars like disciplined growth, prudent risk progression, strong clinical and medical cost performance, and expanding operating leverage.

Total revenue for the first quarter was $965.1 million, up 56% year-over-year. Adjusted EBITDA was $66.3 million, up 82% year-over-year. Non-GAAP adjusted EPS was $0.74, up 76% year-over-year. Free cash flow was just over $64 million. Ended the quarter serving approximately 1.55 million members in value-based care arrangements. Prospect integration remains on track with gross provider retention above 99% for the quarter and tracking towards the high end of $12 to $15 million annual synergy target.

Reaffirm 2026 outlook with total revenue range $3.8 billion to $4.1 billion, adjusted EBITDA $250 million to $280 million, free cash flow $105 million to $132.5 million. Expect second quarter revenue between $965 million and $1 billion and adjusted EBITDA between $65 million and $70 million.

Medicaid and exchange membership attrition risks, adverse selection risk, losses associated with new cohorts and expansion markets, conservative medical cost assumptions.

Q: Jack Sliven asks about enrollment and trend across books.

A: Medicare enrollment mid-single-digit growth, Medicaid disenrollment slightly ahead of range, exchange disenrollments better than expected. Trend performed better than expected across all lines.

Q: Follow-up on capital allocation.

A: Prioritize organic platform investment, disciplined M&A, evaluate share repurchase dynamically.

Q: Ryan Daniels asks about G&A efficiencies and commercialization.

A: AI embedded across workflows, care enablement segment growing, potential for further efficiencies.

Q: Yolanda Singh asks about 2027 EBITDA target and AI investments.

A: Mid-to-high teens organic growth expectation, AI investment split between administrative and clinical with significant part driven by AI.

Q: Craig Jones asks about risk adjustment model.

A: Structurally well-positioned, AI-inferred risk models beneficial.

Q: Michael Howe asks about structural differences with peers in AI.

A: Built AI-native tech platform with integrated data infrastructure, peers lack unified data layer.

Q: David Larson asks about full cap books and stock performance.

A: Full cap books margin maturation, stock performance due to model differentiation and regulatory tailwinds.

Q: Ryan Langthan asks about second quarter guidance and balance sheet.

A: First half profitability consistent, full risk conversions contributing to balance sheet items.

Q: Jean Manheimer asks about prospect synergies and trend.

A: Revenue synergies not quantified, Prospect trend performing better than expected.

Q: Matthew Gilmore asks about full risk contract transition.

A: 40% members in full risk, continued growth expected.

Q: Andrew Mock asks about Medicaid acuity and ACA attrition.

A: Longitudinal patient relationships mitigate adverse selection, ACA attrition better than expectations.